YU17397A - Mezilat trihidrat 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperazinil)1etil)-6-hloro-1,3-dihidro-2h-indol-2-ona - Google Patents

Mezilat trihidrat 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperazinil)1etil)-6-hloro-1,3-dihidro-2h-indol-2-ona

Info

Publication number
YU17397A
YU17397A YU17397A YU17397A YU17397A YU 17397 A YU17397 A YU 17397A YU 17397 A YU17397 A YU 17397A YU 17397 A YU17397 A YU 17397A YU 17397 A YU17397 A YU 17397A
Authority
YU
Yugoslavia
Prior art keywords
piperazinyl
dihydro
chloro
ethyl
benzisthiazole
Prior art date
Application number
YU17397A
Other languages
English (en)
Other versions
YU49398B (sh
Inventor
Frank R. Busch
Carol A. Rose
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU17397A publication Critical patent/YU17397A/sh
Publication of YU49398B publication Critical patent/YU49398B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Abstract

Pronalazak se odnosi na trihidratnu so mezilata 5-(-2-(4-(1,2-benzizotiazol-3-il)-1-piperazinil)-etil)-6-hloro-1,3-dihidro-2H-indol-2-ona, farmaceutske kompozicije koje sadrže navedenu trihidratnu so mezilata i metode korišćenja navedene mezilat trihidratne soli za tretman psihotičkih poremećaja.
YU17397A 1996-05-07 1997-05-06 Mezilat trihidrat 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperazinil)-etil)-6-hloro-1,3-dihidro-2h-indol-2-ona YU49398B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07

Publications (2)

Publication Number Publication Date
YU17397A true YU17397A (sh) 2000-10-30
YU49398B YU49398B (sh) 2005-11-28

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
YU17397A YU49398B (sh) 1996-05-07 1997-05-06 Mezilat trihidrat 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperazinil)-etil)-6-hloro-1,3-dihidro-2h-indol-2-ona

Country Status (46)

Country Link
US (1) US6110918A (sh)
EP (1) EP0904273B1 (sh)
JP (1) JP3102896B2 (sh)
KR (1) KR100333214B1 (sh)
CN (1) CN1092658C (sh)
AP (1) AP838A (sh)
AR (1) AR007003A1 (sh)
AT (1) ATE236902T1 (sh)
AU (1) AU730856C (sh)
BG (1) BG63601B1 (sh)
BR (1) BR9708932A (sh)
CA (1) CA2252895C (sh)
CO (1) CO4940465A1 (sh)
CZ (1) CZ289216B6 (sh)
DE (1) DE69720719T2 (sh)
DK (1) DK0904273T3 (sh)
DZ (1) DZ2221A1 (sh)
EA (1) EA001180B1 (sh)
EG (1) EG24401A (sh)
ES (1) ES2192264T3 (sh)
GT (1) GT199700042A (sh)
HK (1) HK1017893A1 (sh)
HN (1) HN1997000040A (sh)
HR (1) HRP970235B1 (sh)
HU (1) HU229057B1 (sh)
ID (1) ID17504A (sh)
IL (1) IL126590A (sh)
IS (1) IS2301B (sh)
MA (1) MA26427A1 (sh)
ME (1) ME00901B (sh)
MY (1) MY128051A (sh)
NO (1) NO312513B1 (sh)
NZ (2) NZ508303A (sh)
OA (1) OA10908A (sh)
PL (1) PL188164B1 (sh)
PT (1) PT904273E (sh)
SI (1) SI0904273T1 (sh)
SK (1) SK282674B6 (sh)
TN (1) TNSN97073A1 (sh)
TR (1) TR199802241T2 (sh)
TW (1) TW427989B (sh)
UA (1) UA47467C2 (sh)
UY (1) UY24543A1 (sh)
WO (1) WO1997042190A1 (sh)
YU (1) YU49398B (sh)
ZA (1) ZA973875B (sh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
PT985414E (pt) * 1998-05-26 2004-01-30 Pfizer Prod Inc Metodo de tratamento de glaucoma e retinopatia isquemica
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
ATE391507T1 (de) * 2000-06-02 2008-04-15 Pfizer Prod Inc S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
CA2525866A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
EP1530570A2 (en) * 2003-06-03 2005-05-18 Teva Pharmaceutical Industries Limited CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
EP1628973A2 (en) * 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
CN1934108A (zh) 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
PT1720867E (pt) * 2004-02-27 2010-01-28 Ranbaxy Lab Ltd Processo para a preparação de ziprasidona
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
KR100333214B1 (ko) 2002-06-20
BG102893A (en) 1999-09-30
MY128051A (en) 2007-01-31
HUP9902808A2 (hu) 2000-03-28
ME00901B (me) 2005-11-28
AP9700978A0 (en) 1997-07-31
AR007003A1 (es) 1999-10-13
AU730856C (en) 2001-11-15
ES2192264T3 (es) 2003-10-01
NZ508303A (en) 2001-07-27
ATE236902T1 (de) 2003-04-15
GT199700042A (es) 1998-10-02
MA26427A1 (fr) 2004-12-20
EP0904273A1 (en) 1999-03-31
TNSN97073A1 (fr) 2005-03-15
SI0904273T1 (en) 2003-08-31
ID17504A (id) 1998-01-08
TW427989B (en) 2001-04-01
HU229057B1 (en) 2013-07-29
AU730856B2 (en) 2001-03-15
PL329880A1 (en) 1999-04-12
HUP9902808A3 (en) 2000-04-28
KR20000010822A (ko) 2000-02-25
PL188164B1 (pl) 2004-12-31
PT904273E (pt) 2003-06-30
AU1936897A (en) 1997-11-26
CA2252895A1 (en) 1997-11-13
DE69720719D1 (de) 2003-05-15
NO985193L (no) 1998-11-06
NZ332219A (en) 2005-02-25
US6110918A (en) 2000-08-29
HN1997000040A (es) 1997-06-05
EP0904273B1 (en) 2003-04-09
OA10908A (en) 2001-10-26
EG24401A (en) 2009-04-29
IL126590A (en) 2001-11-25
NO312513B1 (no) 2002-05-21
CN1092658C (zh) 2002-10-16
EA199800909A1 (ru) 1999-04-29
CZ289216B6 (cs) 2001-12-12
HRP970235B1 (en) 2002-08-31
SK150598A3 (en) 2000-03-13
JPH11509865A (ja) 1999-08-31
DE69720719T2 (de) 2003-11-06
DK0904273T3 (da) 2003-07-07
SK282674B6 (sk) 2002-11-06
CN1216990A (zh) 1999-05-19
CO4940465A1 (es) 2000-07-24
WO1997042190A1 (en) 1997-11-13
EA001180B1 (ru) 2000-10-30
JP3102896B2 (ja) 2000-10-23
TR199802241T2 (sh) 1999-02-22
UY24543A1 (es) 2000-09-29
YU49398B (sh) 2005-11-28
DZ2221A1 (fr) 2002-12-03
CZ349498A3 (cs) 1999-09-15
BR9708932A (pt) 1999-08-03
HK1017893A1 (en) 1999-12-03
CA2252895C (en) 2002-08-20
ZA973875B (en) 1998-11-06
HRP970235A2 (en) 1998-06-30
IS4878A (is) 1998-10-23
UA47467C2 (uk) 2002-07-15
NO985193D0 (no) 1998-11-06
BG63601B1 (bg) 2002-06-28
IS2301B (is) 2007-10-15
IL126590A0 (en) 1999-08-17
AP838A (en) 2000-05-03

Similar Documents

Publication Publication Date Title
YU17397A (sh) Mezilat trihidrat 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperazinil)1etil)-6-hloro-1,3-dihidro-2h-indol-2-ona
MY119997A (en) Mesylate dihydrate salts of 5-(2-(4-(1, 2-benzisothiazol-3-yl) -1-piperazinyl)-6-chloro-1, 3- dihydro-2h-indol-2-one
IL106777A (en) Monohydrate of 5-(2-(4-(1, 2-benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6- chloro-1, 3-dihydro-2h- indole-2-one hydrochloride and pharmaceutical compositions comprising it
DE69726206D1 (de) Prodrogen von 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-on
PL376721A1 (pl) Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym
SI1556378T1 (sl) Acilni derivati 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperaznil)etil)-6-kloro-1,3-dihidro -2H-indol-2-ona z nevrolepticno aktivnostjo
HUP9902404A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(2H)-indol-2-on (ziprazidon) mezilát-dihidrát sói, a vegyületek előállitása és dopamin D2 antagonistaként történő alkalmazása